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1. Introduction
The pharmaceutical industry’s current challenge to serve public health needs by has become
increasingly difficult due to obstacles that slow down the process of identifying and develop‐
ing new treatments of unmet medical diseases. There are many auspicious new therapies that
have progressed into clinical trials in recent years; they include treatments for cancer, inflam‐
mation, neurodegenerative and psychiatric disorders, anti-infective respiratory and metabolic
disorders, but their development has failed for a number of reasons. Overcoming these
obstacles incurs tremendous costs and takes a lot of time; new therapies must then be identified
get successfully issued into the marketplace. In response, government, academic and phar‐
maceutical industry researchers are looking for new ways to approach the discovery of new
medicines and technologies that will not only combat illness but also improve the quality of
life, a most important outcome of expensive new treatments. Counterbalancing this important
goal are efforts to innovate in the face of increasing public pressure to control costs and increase
the speed with which new medicines arrive on the marketplace.
For a few years now, nanotechnology has emerged as an area of science and technology that
is leading us to a new industrial revolution. Nanotechnology is defined as scientific and
technological development at the atomic and molecular levels, in the range of about 1-100 nm,
to obtain a fundamental understanding of phenomena and materials on a nanoscale and to
create and use structures, devices and systems that have novel properties and functions due
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to their size. The most interesting aspect of nanotechnology is its ability to work with materials
of small size that, however, can change radically on a physical and chemical level at this scale:
electrical conductivity, color, resistance or elasticity, among other properties, behave differ‐
ently than they do in volumetric material. The emergence of nanotechnology in the health
sciences has led to a new discipline called nanomedicine, the main objective of which is the
development of tools to diagnose, prevent and treat diseases when they are still not very
advanced or incipient [1].
Nanomedicine includes three main areas: nanodiagnosis, nanotherapy and regenerative
medicine [2]. Their main goals are explained in the following paragraphs:
a) The purpose of nanodiagnosis is to identify diseases in their initial stages at the cellular or
molecular level and, ideally, down to the level of a single cell, using contrast nanodevices and
systems [3]. Early identification would lead to immediate application of appropriate treatment,
increasing the probability of healing. Nanosystem diagnostics can be used in vitro or in vivo.
In vivo diagnosis normally requires that devices penetrate the human body to identify and
(ideally) quantify the presence of specific pathogen or cancer cells, for example. This entails a
number of problems associated with the biocompatibility of the material of the device, as well
as sophisticated design to ensure effectiveness and minimize side effects. Meanwhile, the in
vitro diagnosis provides greater design flexibility of design because it can be applied to very
small samples of body fluids or tissue from which specific detection can be performed
(pathogens or genetic defects, for example) in a very short time with high precision and
sensitivity [4]. Because of these fundamental differences, in vitro detection using nanoscale
devices is expected to reach the market faster and consolidate more easily than in vivo methods.
There are two main areas of work: images and nanosystems and biosensors. These systems
rely on the use of nanoparticles, semiconductors, or magnetic metals, such as contrast agents
for in vivo labeling. These new systems can increase sensitivity and give better contrast in
imaging techniques. One of the first proposed nanoparticle systems was the identification of
tumor cells. In the case of nanodiagnostics, the main testing devices being developed are
nanobiosensors, devices capable of detecting in real time without the need for fluorescent or
radioactive markers and with high sensitivity and selectivity all kinds of chemical and
biological substances [5].
b) The aim of nanotherapy is to drive nanosystems containing recognition elements to act or
transport and release drugs exclusively in cells or affected areas in order to achieve a more
effective treatment, minimizing side effects [6]. Approximately 40% of the novel new molecules
(NNMs) selected for full-scale development based on their safety and efficacy data fail to reach
the clinical development phase due to poor biopharmaceutical properties, which translate into
poor bioavailability and undesirable pharmacokinetic properties. Several nanotechnology-
based products, including Doxil® (doxorubicin HCl liposome injection) and Abraxane®
(paclitaxel protein-bound particles for injectable suspension) are already on the market [7, 8].
In addition, Baxter and Elan are promoting Nanoedge® dispersion technology and Nano‐
Crystal® technologies respectively, so as to improve the biopharmaceutical properties of orally
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administered therapeutic agents [9]. Nanotechnology can play an important role in the
development of proper formulations that address the drug delivery issues related to NNMs
with poor biopharmaceutical properties, such as poor solubility, poor permeability across the
intestinal epithelium, enzymatic or nonenzymatic degradation/metabolism, complexation
with chelating ligands or metal cations, intestinal efflux, and poor transport properties.
Additionally, nanotechnology can also achieve desirable pharmacokinetic and toxicological
properties that aid in the accelerated development of the NNM. Nanoparticulate drug delivery
systems are being used to alter the drug’s biopharmaceutics and pharmacokinetics such as
drug absorption, distribution, metabolism, and elimination [10]. Examples of nanoscale
delivery systems include polymeric nanoparticles, liposomes, nanoemulsions, micelles, and
dendrimers.
A number of nano-delivery systems are designed to encapsulate the drug in carriers (e.g.,
liposomes, micelles, polymeric nanoparticles, and dendrimers), which masks the unfavorable
biopharmaceutical properties of the molecule and replaces them with the properties of the
materials used to make the nano-delivery system. These approaches were used for a number
of poorly soluble NNMs in aqueous phase or easily degraded and metabolized NNMs.
Another approach involves the covalent conjugation of the molecules with carrier and
targeting moieties (e.g., polymer-drug conjugate, antibody-drug conjugates, solubilizers-drug
conjugates, etc.) that override the drug’s poor biopharmaceutical properties and improve the
pharmacokinetics and biodistribution. This approach was used for site-specific or targeted
delivery to alter the pharmacokinetics of the drug by increasing the plasma elimination half-
life, preventing degradation or metabolism of the drug in the systemic circulation, and possibly
altering the organ and subcellular distribution of the drug, thus alleviating unwanted toxicity
due to nonspecific distribution, improving patient compliance and providing favorable clinical
outcomes [11]. Advances in nanomedicine are also applied for site-specific drug and gene
delivery strategies, especially for the treatment of cancer and other life-threatening diseases
[12, 13]. The nanotechnology approach, although expensive and time consuming, can signifi‐
cantly assist in the accelerated development of NNMs with adequate druglike properties and
can assist the pharmaceutical companies in adding more lead molecules to their pipeline. One
of the major challenges in this process is the development of "nanotherapies”, specifically those
targeting diseased tissues and organs while avoiding damage to surrounding healthy cells
and, thus, the dreaded side effects of current treatments.
c) Regenerative medicine aims to repair or replace damaged tissues and organs using nano‐
technology tools [14]. Regenerative nanomedicine deals with the repair or replacement of
damaged or diseased tissues and organs by applying methods derived from gene therapy, cell
therapy, chemical dosage and bio-regenerative tissue engineering, stimulating the human
body’s very own repair mechanisms [15]. The main contributions of nanotechnology to
regenerative medicine are related to the production of new materials and support systems, the
use of embryonic and adult stem cells, and the production of bioactive molecules that serve as
signals for cell differentiation [16]. Nanotechnology can play a dominant role in tissue
engineering by facilitating new materials and techniques that allow fro more efficient tissue
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integration and the ability to generate microenvironment parts that are particularly conducive
to tissue regeneration. The main difficulty lies in finding suitable materials that allow for the
fabrication of structures that remain active while the affected organ regenerates the damaged
area [17]. Some of the materials that are being used include carbon nanotubes, the nanoparticles
as hydroxyapatite or zirconia particles, biodegradable polymer nanofibers, nanocomposites,
etc. One of the greatest achievements is the development of biomaterials with the ability to
mimic the extracellular matrix, forming a real support identical to what appears naturally in
cells and on which stem cells can be grown for subsequent implant in patients to repair or
replace damaged organs.
The enormous advances in nanotechnology during the past decades have allowed for sub‐
stantial developments in the field of health sciences. The systems and methods described are
only selected examples of the enormous activity that is taking place in thousands of laborato‐
ries around the world to improve health and quality of life across the whole of society. In the
present chapter, we discuss the pharmacokinetic properties and safety of cadmium-containing
quantum dots as tools for diagnosis and drug delivery systems.
2. Quantum dots in medical science
Quantum dots (QDs) have aroused much interest in recent years, especially in view of their
potential applications in biology and medicine [18]. This heterogeneous class of engineered
nanoparticles that are both semiconductors and fluorophores is rapidly emerging as an
important type of nanoparticles with numerous potential applications in medicine [19]. QDs
are semiconductor inorganic nanomaterials ranging from 1–10 nm. They contain elements
found in groups II–IV (e.g., CdSe, CdTe, CdS, and ZnSe) or III–V (eg, InP and InAs) of the
periodic table. QDs have fluorescent properties that offer superior features to conventional
organic dyes, including high quantum yield, broad absorption, and narrow emission spectra
(Figure 1). QDs are more photostable than conventional fluorophores; e.g., it has been reported
that, under the same excitation conditions, 90% of the fluorescence of a normal organic dye
fades within 1 minute, whereas the fluorescence of QDs remains intact even after 30 minute
or more [20].
In terms of their basic structure, QDs consist of an inorganic core, an inorganic shell and
aqueous organic coating. The size of the inorganic core determines the wavelength (color) of
light emitted following excitation (Figure 1). The inorganic shell is responsible for increas‐
ing the photostability and luminescent properties of the QDs [21]. The photo stability of the
inorganic shell has allowed QDs to be used as probes for imaging cells and tissues over long
spans of time. While there are many useful features to QDs, there are also a number of issues
related to their structure and function [22]. One of the most problematic is a phenomenon
known as “blinking”. This is the term used to describe the alternation between the light-
emitting and –non-emitting state of the QD. This factor limits the number of photons that
can be detected in a given time period and it also contributes to unpredictable photon arrival
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times. It has been proposed that this feature of QDs could be suppressed by “passivating”
the QDs’ surface with thiol moieties, polymers, or by using the QDs in free suspension. A
standard nomenclature is generally utilized to describe the component parts of various QDs:
Core/Shell or Core/Shell-Conjugate. For example, a QD with a cadmium-sulfide core and a
maltodextrin shell which has been protein conjugated would be designated as CdS/protein
[23].  As fluorescent  particles,  quantum dots  can be detected and tracked with the same
approach  developed  for  organic  fluorophores.  All  the  technical  development  has  been
directly  transposed  to  QD  imaging  and  tracking.  Biomedical  applications  exploit  the
fluorescent properties of QDs, particularly their advantage over traditional organic dyes for
both diagnostic and clinical applications. The in vitro  biomedical and diagnostic applica‐
tions of QDs include such techniques as the multicolor fluorescent labeling of cell surface
molecules and cellular proteins in microscopy and other applications, detection of patho‐
gens and toxins, DNA and RNA technologies, and fluorescence resonance energy transfer.
QDs are also being explored for use in whole-body in vivo imaging of normal and tumor
tissues. QDs may also find use in therapeutic applications such as targeted drug delivery,
photodynamic therapy, and drug discovery [24].
Figure 1. Spectrum and basic structure of quantum dots. (a) Emission spectra of quantum dots; (b) Schematic struc‐
ture of quantum dots and conjugation to biomolecules.
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3. Cadmium-containing quantum dots
Different results by various research groups indicate that cadmium (in group III–V) is
extremely toxic if allowed to leach into the environment and this material also has DNA-
damaging properties [25]. Other studies have shown that using cadmium in the cellular
environment may lead to the formation of reactive oxygen species, resulting in cell death [26,
27]. The stability of groups III–V is known to be due to the presence of covalent rather than
ionic bonding. The most optically suitable emitting ‘core’ materials have been cadmium-based
materials. Cadmium selenide, Cadmium sulfide or Cadmium telluride particles provided
bright emission across the visible and near infrared regions of the electromagnetic spectrum
[28]. Questions have arisen regarding the suitability of cadmium-containing materials as
biological labels. Other problematic factors include the suitability of the capping agents, the
retention of particles over a certain size, biological magnification and, importantly, the
breakdown and decomposition products of these inorganic materials. QDs are notoriously
labile and the identity and ultimate destination of the inorganic decomposition products
remains unclear. Despite this, cadmium-containing quantum dots provide a genuine advance
in medical imaging and the numerous problems involving these particles are almost imme‐
diately dispelled if one wishes to image and explore fixed cells [29, 30].
Cadmium, which is the main component in the majority of quantum dots, is known to be
acutely and chronically toxic to cells and organisms. In cells, it is taken into calcium membrane
channels, where it accumulates [31]. Cadmium inhibits the synthesis of DNA, RNA and
proteins, as well as breaking up DNA strands and mutating chromosomes [32]. On a cellular
level, cadmium induces oxidative stress by depletion of endogenous antioxidants such as
glutathione [33], as well as mitochondrial damage [34]. Cadmium nanoparticles exposure can
lead to disturbances in cellular homeostatic mechanisms, resulting either in adaptive cellular
responses or cell death. Cell death can occur either through an abrupt process named necrosis
or a tightly regulated or programmed process (apoptosis and autophagy) [35]. Its toxicity is
mainly associated with liver and kidney injury, osteoporosis and neurological dysfunctions at
the level of living organisms. The toxic ions are commonly thought to be released from
quantum dots when the surface of the nanoparticle is oxidized and early reports on the
inclusion of simple quantum dots in bacteria support this [36]
Protecting the core can, to some degree, control toxicity related to cadmium leakage. However,
the change in the physicochemical and structural properties of engineered quantum dots could
be responsible for a number of material interactions that could also have toxicological effects
[37, 38]. However, encapsulation is not simple and it has been reported that quantum dots
have displayed toxicity even with well-protected cores. Recently, polymers that can act as
coordination sites for cadmium ion aggregation have protected semiconductor nanoparticles.
CdS nanoparticles protected with starch and, in particular, amylose, form a wide range of
inclusion complexes for numerous guest molecules [39]. Soluble starch added during the
synthesis has been used as a capping agent in the synthesis of CdS and CdSe nanoparticles,
resulting in well-controlled and uniform particle sizes of cadmium-rich nanoparticles [40].
Early studies attempted to quantitatively determine values for the onset of cytotoxicity in CdSe
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and CdSe/ZnS quantum dots, either coated with mercaptopropionic acid (MPA), embedded
in a silica shell or embedded in an amphiphilic polymer shell [41]. They found that the majority
of the nanoparticles were ingested into the cells and were stored in vesicles around the nucleus,
irrespective of the surface coating. We have previously synthesized CdS nanoparticles coated
with maltodextrin polymer, and our results revealed that CdS-MD nanoparticles produced
distinct dose-dependent effects (Figure 2) [42]. It is clear from this and other studies that the
surface coating is related to the toxicity experienced by cells, which affects the level of toxic
material released from the nanoparticles. Other studies have shown that different cell types
have varying thresholds for quantum dot-induced toxicity.
Figure 2. CdS/maltodextrin quantum dots. (a) Schematic structure of CdS/maltodextrin quantum dots; (b) Characteri‐
zation of different sized CdS/MD quantum dots using TEM; (c) Spectra of CdS/MD quantum dots, the maximum lumi‐
nescence of which is a wavelength of 520 nm (CdS/MD520); (d) HepG2 cells observed under fluorescent microscopy
at (x40) magnification.
4. Biocompatibility and functionalization of cadmium-containing
quantum dots
Biocompatibility is a word that is used extensively in biomaterials science. The incorporation
of QDs into biological systems often requires strategies for the manipulation of the ligands
bound to the surface of the QDs surface in order to make them water-soluble and biocompat‐
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ible, compatible with living tissue or a living system by not being toxic, injurious, or physio‐
logically reactive [43]. QDs must be rendered water-soluble through the modification of their
surface in preparation for biological applications. An ideal water-soluble ligand should meet
the following requirements: (1) provide QDs with stability and solubility in biological buffers;
(2) maintain a high resistance to photobleaching and other photophysical properties in
aqueous media; (3) have functional groups which are able to conjugate to biomolecules; (4)
minimize overall hydrodynamic size. The stability of QDs in water can be obtained through
either a complete ligand exchange procedure, or through steric stabilization where the native
hydrophobic surface is coated with amphiphilic molecules and/or polymers [44, 45].
QDs have been adapted to the desired application by conjugation to a recognition moiety, e.g.,
antibodies, peptides, oligonucleotides or aptamers, or by coating with streptavidin. Several
functionalizations have been adapted to the shell layer coating the core, making the core/shell
QDs most adaptable for biological applications [46]. In order to suitably functionalize the QDs,
there are several methods that have been successfully used for conjugation of QDs to the
desired biomolecules. These include electrostatic attraction, covalent linkage, adsorption, and
mercapto (-SH) exchange [47]. The choice depends on the features of the biomolecule of
interest; for example, thiol-containing biomolecules can be conjugated to QDs via mercapto
exchange. In contrast, simple small molecules such as oligonucleotides and various serum
albumins were found to readily adsorb non-specifically to the surface of water-soluble QDs.
The factors affecting the adsorption are pH, ionic strength, temperature, and surface charge of
the molecules [48]. There are three primary ways to target a biocompatible and functional
quantum dot: with antibodies, with peptides, or with small molecules. The simplest labeling
strategy uses antibodies; the most complicated is that of small molecules, as this approach
usually requires more synthetic chemistry. Each approach has its advantages and disadvan‐
tages, and no approach is a universal solution.
Chemical conjugation of antibodies to semiconductor QDs is attractive because the proteins
of interest can be visualized. For conjugation of QDs to antibodies, the orientation of the
antibody on the QD is important given its functionality as a targeting moiety. The conjugation
strategy contributes to the control of antibody orientation. For example, the use of biotinylated
antibodies and streptavidin-coated QDs provides no control over the orientation of the
antibody on the surface of the QD owing to the presence of multiple biotinylation sites on the
antibody. Antibody-quantum dot conjugates have been used in a myriad of applications [49,
50]. An immunoassay for the detection of hepatitis B surface antigen [51] conjugated
CdTe/CdS QDs to anti-hepatitis B surface antigen antibodies using protein G as a linking
bridge, instead of covalently linking the QDs to the antibodies. Other studies developed a
microplate immunoassay for detection of the cardiovascular marker C-reactive protein in 104
serum samples, with a limit of quantification of 0.19 μg/l within 1.5 h [52]. A multiplex
immunoassay for the simultaneous detection of staphylococcal enterotoxin B and chicken IgY
(IgG) in the same well of a 96-well microtiter plate was also undertaken [53]. A multiplex
fluoroimmunoassay for the detection of lung cancer markers—neuron specific enolase (NSE)
and carcinoembryonic antigen (CEA) in human serum—was recently developed [54]. A wide
selection of antibody-quantum dot conjugates is also commercially available. Disadvantages
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to this approach include the availability of antibodies, their selectivity and affinity, and the
increased hydrodynamic radius of the quantum dot conjugate. Nonetheless, antibody-QD
conjugates are often the method of choice and make up much of the QDs in biology literature.
Peptides can also be conjugated to QDs in a direct approach by linking to thiol-rich domains.
A direct binding approach was used to bioactivate and solubilize QDs with phytochelatin-
related peptides [55]. Peptide-functionalized quantum dots have been successfully used for
targeting cellular proteins such as growth factor receptors, G protein-coupled receptors,
integrins, and ion channels [56, 57]. In particular, ~30-50 arginine-glycine-aspartatic acid (RGD)
peptides have been conjugated to NIR quantum dots to specifically target αvβ3 integrins in
mouse tumor neovasculature in vivo [58], while other studies have relied on high-affinity
peptide neurotoxin quantum dot nanoconjugates to image endogenous proteins in living cells
and ex vivo tissue [59]. Overall, peptide-quantum dot nanoconjugates offer distinct advantages
over antibody-mediated targeting, and their potential as biological probes is being actively
explored. On the other hand, a single QD can be conjugated to multiple protein molecules,
which can be similar or different depending on the intended application. Approximately 15-20
maltose binding proteins, a 44-kDa protein measuring 3 × 4 × 6.5 nm, can be attached to a single
6-nm QD [60]. Because of their brightness and photostability, water-stabilized QDs have been
used to track many receptor-mediated endocytic trafficking events in live cells using fluores‐
cence microscopy [61]. For example, QDs conjugated to EGF have been used to track the
dimerization of the EGF receptor (EGFR) and its ability to elicit downstream signal transduc‐
tion events [62]. Biotinylated α-bungarotoxin was bound to streptavidin-conjugated QDs to
characterize the assembly dynamics of acetylcholine receptor clusters in postsynaptic mem‐
branes [63]. Recently, high-resolution imaging methods in the nanometer range have been
developed to image the membrane transport and dynamics of tumor cell proteins during
metastasis in living mice using antibody-conjugated QDs [64]. This technology can also be
applied to detecting cancer cells in sentinel lymph nodes in whole animals using QDs conju‐
gated to tumor-specific molecules [65]. One can envision several ligand-conjugated quantum
dots, with each ligand conjugated to a different size (color) quantum dot, allowing a multi‐
plexed fluorescent assay for drug discovery.
Different schemes have been developed to conjugate ssDNA and dsDNA to the surface of QDs.
DNA-QD conjugates retain the selectivity of DNA and the photophysical properties of QDs,
allowing detection of single or multiple DNA targets. DNA–QD conjugates require solubility
in water, stability under physiological conditions and minimal nonspecific DNA binding to
the QD surface. The thiol-modified oligonucleotide can be conjugated to QDs in a direct ligand
exchange approach (native cap exchange) where the oligonucleotide displaces the surface-
bound mercaptopropionic acid and yields aqueous stable and strongly fluorescent oligonu‐
cleotide bound QDs [66]. Applications of QDs include in vitro diagnostics, imaging and
therapeutics. QDs are used as labels in immunoassays, immunohistochemical staining, cellular
imaging and multiplex diagnostics.
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5. Cadmium-containing quantum dots as a platform for nanoparticle drug
delivery vehicle design
Recently, there has been an explosion in the development of nanoparticle-based drug delivery
vehicles composed of lipids, polymers, carbon materials, and even hybrid combinations of
those materials tailored not only for the dramatic improvement of the pharmacological
properties of existing drugs, but also for enabling the delivery of new classes of potent anti-
cancer drugs for gene therapy and immunotherapy [67, 68]. With QDs, a combination of unique
physical, chemical, and optical properties facilitates in-depth study of nanocarrier interactions
with biological systems through real-time monitoring of QDs biodistribution, intracellular
uptake, drug release, and long-term nanocarrier fate. At the same time, compact size and
compatibility with a variety of surface modification strategies enables substitution of virtually
any QD core with a QD within single-nanoparticle drug delivery vehicles, or incorporation of
QD tags within larger multicomponent vehicles. The combination of superior brightness and
resistance to photo-degradation represents another set of QD properties that highly useful for
long-term nanocarrier tracking.
The great interest in engineering NP-based drug delivery vehicles is driven by the powerful
capability of nanocarriers to completely redefine the pharmacokinetic properties of virtually
any drug, ranging from small-molecule therapeutics to large proteins and DNA plasmids.
Encapsulation of the drug within the nanoparticles keeps it shielded from the biological
environment until the moment of carrier degradation and drug release, thus minimizing non-
specific and potentially adverse interactions en route to the target [69].
A few reports have appeared recently regarding this ambitious goal. It has previously
conjugated captopril, an antihypertensive drug, to the QD surface and studied its pharmaco‐
dynamics and pharmacokinetics in stroke-prone spontaneously hypertensive rats [70]. The
results show that the administered QD-captopril conjugates are capable of decreasing rat blood
pressure to the same extent as the captopril alone in the first 30 min, but the therapeutic effect
of QD-captopril disappears after 60 min. It is unclear whether the therapeutic effect results
from the QD-captopril conjugates or captopril molecules detached from the QD surface.
Another piece of interesting work was previously reported, wherein a targeting functionality
was added to QDs by linking them with RNA aptamers (A10) that specifically bind to prostate
specific membrane antigen (PSMA) [71]. Doxorubicin, a DNA-interacting drug widely used
in chemotherapy, was immobilized onto QDs by intercalation within the A10 RNA aptamer
[72]. Another study reported the ability of nanoconjugates of CdSe/CdS/ZnS and doxorubicin
(Dox) to target alveolar macrophages, cells that play a critical role in the pathogenesis of
inflammatory lung injuries. The results demonstrated that nanoparticle platforms can provide
targeted macrophage-selective therapy for the treatment of pulmonary disease [73]. This was
previously reported regarding siRNA delivery using QDs as delivery vehicles [74].
QDs already play an important role in fundamental biology and in vitro disease diagnostics
and prognostics. Their unique structural and surface properties, such as their tunable and
uniform size, flexible drug-linking and doping mechanisms, large surface-to-volume ratio and
wide spectrum of surface reactive groups have enabled a new avenue of research: targeted
Application of Nanotechnology in Drug Delivery478
and traceable drug delivery. However, high-quality QDs are mainly made with heavy metals,
like cadmium, whose long-term toxicity is currently largely unknown. Despite this limitation,
QDs have been applied to cells and small animals as drug carriers, serving as an outstanding
discovery tool for drug screening and validation, and as prototype materials for drug carrier
engineering [75]. One primary challenge of drug delivery is maintaining a useful concentration
of the drug in the targeted tissue while preventing toxicity.
6. Pharmacokinetics of cadmium-containing quantum dots
Nanoparticle-based drug delivery is on its way to overcoming the fundamental limitations of
simple free drug formulations, providing means to change their pharmacological properties
and also understand their biological fate in great detail. Among many contrast agents for
studying nanoparticle-based drug delivery vehicles, QDs are particularly suitable. Their
unique amalgamation of useful features, such as small size, versatile surface chemistry, and
exquisite optical properties make them an ideal platform for the comprehensive characteriza‐
tion of nanoparticle-based drug delivery vehicle behavior across single-cell to whole organism
levels. In this new field, QDs have already made substantial contributions, enabling dynamic
monitoring of nanocarrier cell uptake, intracellular distribution, circulation half-times, and
biodistribution. Early on, the design of QDs drug delivery vehicles was governed by the
intrinsically poor pharmacokinetic (PK) properties of conventional drugs. Low drug solubility,
rapid metabolism and clearance and, most importantly, a lack of selectivity, regularly lead to
therapeutic failure by causing severe systemic toxicity in healthy tissues, thus prohibiting the
dose escalation necessary to eliminate tumor cells. Incorporating these drugs into nanocarriers
offers an exciting opportunity to redefine the PK properties, improving therapeutic efficacy
and reducing side effects.
When we utilize a nanopharmaceutical, it is important to realize that, in contrast to delivering
a drug that is an organic molecule, we are delivering something of a discrete entity in a
nanoparticle-comprised of atomic scale parts. Due to the quantum effects and electronic
interactions that predominate at the nanoscale, we need to alter the way in which we think
about pharmacological parameters in order to adapt to nanoscience. Nanopharmacology is
further complicated by the need to establish the behavior of nanoparticles such as QDs within
the traditional pharmacological parameters of absorption, distribution, metabolism and
excretion (ADME). Nanoconstructs, in many cases, have limited metabolism and excretion and
persist in biological systems; this becomes particularly important when toxic atoms such as
cadmium are involved. The pharmacological parameters of the behavior of cadmium-
containing quantum dots in biological systems is currently still under investigation. Dosing
parameters, absorption, distribution, metabolism and excretion require considerable further
study, since we have little information on these parameters at this point.
The first factor we need to establish before we study the pharmacokinetics parameter is the
dose. Adequate estimates of QDs exposure during treatments such as cancer therapy must be
in place so that both pharmacological and toxicological studies can be conducted within a
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physiologically relevant dose range. Importantly, how does cadmium content relate to dose?
To date, these parameters have not been rigorously addressed. Dose metrics of QDs have been
reported in terms of mg/kg (or mg/ml for in vitro studies) or on a molar basis, and this will no
doubt need refinement. Given that a QD, or any other nanoparticle, is an engineered entity or
“mini-reactor”, dose via mass or molar number may be an inappropriate descriptor. The length
and extent of QDs tissue retention is an important parameter for dosing considerations, since
repeated doses may induce systemic accumulation, contributing to potential toxicity. Further‐
more, persistence of QDs in tissues demands long-term studies to accurately assess risk.
Therefore, the dose is another parameter that requires consideration.
The second factor to establish is the route of administration. This, along with the risks for
exposure and possible toxicity should be addressed cautiously to ensure experimental and
clinical safety. Moreover, an understanding of possible interactions of QDs within human
tissues may shed light on the prevention of health risks in the laboratory and daily exposure
to QDs. To date, research has established that various nanoparticles can enter an organism
through skin, inhalation, oral delivery, and parenteral administration. Intravenous injection
is a major route for drug administration. It has been reported that intravenously injected QDs
may accumulate in unintended tissues, which implies that the potential toxicity might result
from a failure to clear them from the body [76]. The possibility of tissue uptake of QDs via
ingestion following exposure has also been proposed in animal and cell culture models. Skin
is another important portal of entry for nanoparticles as potential route of systemic drug
administration.
The abilities of nanoagents to penetrate the skin barrier are debatable. Some studies indicate
that NP penetrate skin barrier under skin lesions, UV sunburn or ultrasound [77]. The potential
beneficial and/or side effects of intradermally accumulated NP primarily depend on their
localization in the tissues. It is also important to elucidate further migration pathways of
particles, as this would determine their pharmacokinetic properties and systemic distribution
in the organism. Topically applied QDs were reported to accumulate in the dermis and muscles
[78]; however, a more detailed localization of particles has not been described. Other studies
reported that the majority of the intradermally injected QDs remained at the injection site and
a minority of QDs migrated into lymph nodes, highlighting QDs advantages for lym-phatic
imaging [79, 80]. However, high retention of QDs at the injection site raises concerns about
long-term physiological effects. There is a lack of in-depth analyses of QDs localization and
migration pathways in the dermis. It was recently reported that the subcutaneous injection of
CdSe/ZnS coated with mPEG-5000 polymer into the CDF1 of mice showed that basement
membrane and dense connective tissue fibers limited the diffusion of QDs in the dermis [81].
Negligible QDs penetration into the epidermis, hair follicles, sebaceous and sweat glands,
nerves and blood vessels was also observed. However, low permeation of QDs through the
tissues could result in slow clearance and raises the risks of potential immune, inflammatory
and cytotoxic responses.
The cornea is another common route of drug administration and also an important route of
nanoparticle exposure in occupational scenarios and daily life. However, the possibility of QDs
penetration into the cornea has not been discussed before. It has been previously demonstrated
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that specific QDs influence corneal stromal cell viability up to a significant magnitude of 50%
in a relatively low concentration (5-20 nM) and under a short exposure period (24-48 h) [82].
QDs can also be retained in the cornea up to 26 days in an in vivo mouse model. Therefore,
since corneal stromal cells are crucial for the maintenance of the health and transparency of
the cornea, potential QDs cytotoxicity due to bioaccumulation is a major concern given the
potential threat to corneal health.
Absorption via tissues and biological fluids is generally the first hurdle to be met and this is,
of course, dependent on route of delivery. Currently, the most important route of delivery for
QDs appears to be systemic distribution through parenteral delivery [83]. Nanoparticles are
considered to absorb more effectively into the respiratory, skin, and gastrointestinal systems
than micron-sized particles because of their unique physicochemical properties, such as their
size and surface modifications [84]. For example, instillation of 5 nm QDs shows faster
translocation to other organs than in the case of 27 nm QDs [85]. In addition, a recent study
showed that nanoparticles were only translocated into the circulation system when adminis‐
tered into the lung; their absorption rate varied, depending on their surface properties [86].
When different sizes of polystyrene QDs were administered orally to rats, the absorption of
50–100 nm polystyrene QDs was about 250-fold higher than the absorption of larger micro‐
particles (500 nm, 1, and 10 μm) [87]. Oral administration of different sizes of colloidal gold
particles to mice showed size-dependent absorption [88]. Regarding surface modification,
positively charged particles show better absorption than neutral or negatively charged
particles [89]. However, in a recent study using gold nanoparticles, negatively charged
particles showed higher absorption rates than positively charged particles [90]. Therefore, no
general rule can be made about absorption from these results and further studies on the impact
of surface modification on gastrointestinal absorption are required. Studying the kinetics of
nanoparticles is an important issue in nanotechnology.
Regarding distribution, one of the first elements that parenteral delivered QD will encounter
is the environment of the blood. Here, we have little to no information about blood/QD
interactions. Plasma half-life is no doubt related to surface coating and addition of biological
targeting ligands, if any. For example, PEG coating was reported to increase plasma half-life
[91]. In the case of oxide nanoparticles, many are coated with endogenous plasma proteins
immediately upon entry into the circulatory system and this appears to enhance tissue
delivery. However, the interactions between QDs and plasma proteins are unknown. Immune
responses may also be triggered at this level, as reviewed by [92], but the precise interactions
of QDs at this level have not been examined. Recently, some studies have investigated the in
vivo biodistribution of QDs [93-95]. All of the reports in the literature unanimously conclude
that QDs show a preference for deposition in organs and tissues and that they do not remain
circulating in the bloodstream [96]. Real-time imaging of live animals treated with the
hyaluronic acid (HA)-conjugated QDs showed that the luminescence of NIR QDs could be
detected for up to 2 months [97]. Others reported that QDs coated using an amphiphilic
poly(acrylic acid) polymer remain fluorescent after at least four months in vivo [98].
Organ-selective biodistribution and elimination routes of synthesized QDs coated with 3-
mercaptopropionic acid (QD MPA) and commercially available Qtracker 705 nontargeted
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quantum dots with poly(ethylene glycol) coating (QD PEG) were recently compared after
intravenous injection to mice. QDs were deposited mainly in liver, spleen, kidney and lymph
nodes [99]. Another study observed that, in the murine model, quantum dots (CdSe 100 pmol/
kg) administered by intravenous injection mainly accumulated in the red pulps of the spleen,
portal areas of the liver, and adrenal glands of the kidney within 1 h. It is believed that quantum
dots do not degrade, as evidenced by the intensity of the fluorescence in the fluorescence
spectrum image and comparable intensity profile of Cd [100]. One consistent theme in the
existing literature is that QDs are eventually taken up by the reticuloendothelial system,
including the liver, spleen, and lymphatic system [101]. On the other hand, it has been found
that aqQDs are initially accumulated in liver after short-time (0.5- 4h) post-injection, and then
are increasingly absorbed by kidney during long-time (15 – 80 days) blood circulation.
Moreover, size-dependent biodistribution is obviously observed: aqQDs with larger sizes are
more quickly accumulated in the spleen [102]. We have recently found that after i.p. injection,
the CdS/Maltodextrin quantum dots mainly accumulated in the liver, kidney, spleen, thymus,
intestine, lung and brain (Figure 3). The pharmacokinetics studies showed the presence of CdS/
Maltodextrin in kidney 30 min after administration; at 18 h, the presence of quantum dots in
kidney was more abundant. However, the amount of CdS/Maltodextrin quantum dots in liver
was lower than in kidney, and the maximal presence was at 3 h. Our results suggest that the
transition of CdS/Maltodextrin quantum dots via the liver is very fast, and the main route of
elimination is renal (Figure 4).
Figure 3. Biodistribution of CdS/Maltodextrin in Wistar rats. Tissue distribution of CdS/maltodextrin quantum dots af‐
ter i.p. administration of 10 μg during 8 days. Quantum dots were observed in all analyzed tissues, including brain. The
maximal observed presence of quantum dots was in lung and kidney.
Application of Nanotechnology in Drug Delivery482
Figure 4. Biokinetics of excretion of CdS/maltodextrin quantum dots after a single i.p. administration of 10 μg in kid‐
ney and liver.
The blood–brain barrier (BBB), is a critical interface and acts as a physical and metabolic barrier
between the CNS and the peripheral circulation that serves to regulate and protect the
microenvironment of the brain. The primary function of the normal BBB is to establish and
maintain homeostasis in the CNS [103]. Under normal physiological conditions, BBB prevents
transport of bacteria, large molecules, and most small molecules into the brain. To be BBB
permeable, molecules need to be lipid soluble and less than 400 Da in size. There are more than
7000 drugs in the comprehensive medicinal chemistry database, and only 5% of these drugs
can be used to treat the CNS diseases. In a related study, 12% of all drugs are shown to be
active in the CNS, but only 1% of all drugs are active in the brain for diseases other than affective
disorders [104]. The importance of developing new approaches to brain drug development is
illustrated by considering the limitations of the existing brain drug delivery strategies.
Therefore, there is great interest in nanomedicine to develop optimized traceable drug-loaded
nanoparticle formulations that can be safely used to facilitate drugs across the BBB for treating
brain diseases and, at the same time, visualizing the distribution profile of the nanoparticles
in the brain. The use of QDs bioconjugates as efficient targeted probes for transmigration across
the BBB has been previously demonstrated [105]. Since the transferrin receptor protein is
highly localized on the endothelial surface of the brain, transferrin (Tf) was selected to trigger
receptor-mediated transport across the BBB. It was discovered that the migration rate of Tf-
conjugated QDs crossing the in vitro BBB is both concentration-and time-dependent [106]. It
was recently demonstrated that the QDs-Tf-Saquinavir nanoformulation increases the drug
solubility, enhancing systemic bioavailability, while the excellent optical properties of QDs
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also visualize the distribution and accumulation of nanoplexes in brain [107]. Such primary
results offer a basis for the development of novel QDs with targeting molecules and drugs,
which could enhance drug delivery efficacy across the BBB and facilitate the uptake of the QD-
drugs in the brain. Despite the encouraging results on the use of QDs for drug delivery across
the BBB, there is still serious concern regarding QDs toxicity in vivo, which mainly originates
from the intrinsic, potentially toxic nature of the semiconductor materials themselves.
On the other hand, the placental barrier protects the embryo from various chemical agents and
other foreign substances in the body. However, the passage of xenobiotic molecules through
the placental barrier is not completely prevented, and drugs may affect fetal cell proliferation,
embryonic growth, and organ formation [108]. Knowledge regarding embryotoxicity is of
great importance because it is a necessary part of the toxicological profile that must be
established for any new biologically active substance relevant to human safety. There are many
studies in this field [109-111], but the detailed effects of NPs still pose many questions. A
decrease in embryonic weight after QDs injection on the sixth day of embryogenesis
(CdSe/ZnS QDs, 9.6%; CdT QDs, 6.2%) has been reported, and no embryotoxic or teratogenic
effects were observed at any stage of embryogenesis [112]. Others have shown that NPs (nSP
and TiO2s 70 nm and 35 nm in diameter, respectively) can cross the placental barrier in
pregnant mice and cause neurotoxicity in their offspring [113]. They showed that the NPs were
found in the placenta, fetal liver, and fetal brain. Other authors argue that some NPs (CdSe
and CdTe/CdS) in different sizes, at different dosages, and with different outer capping
materials can increase the rate of early-stage blastocyst death in mice and can be potentially
transferred across the placenta to the fetus [109, 114]. These studies show that NPs can enter
the embryo through the placenta, which is a natural barrier for a large variety of organic
substances with diverse molecular structures. The NPs, which appear in the maternal body
during pregnancy, can cross the placental barrier and may even cause developmental deform‐
ities. Recently, we demonstrated that CdS-MD nanoparticles were embryotoxics in a chicken
embryo model (Figure 5) [42]. The nature of the observed abnormalities suggests that these
effects could be directly associated with concentration. Therefore, according to the observed
effects, the prolonged accumulation of quantum dots in the maternal organism may increase
the risk of adverse effects on embryo development.
The liver is know to have a high capacity to metabolize and degenerate a multitude of
xenobiotics. The binding of proteins plays a key role in delivering xenobiotics from plasma
into the liver. In addition, the reticuloendothelial system (RES) can phagocytose particles larger
than 100 nm and then transport the particles into the liver in vivo. Metabolism of QDs is yet
another understudied aspect of cadmium QDs. The QD cores do not appear to be subject to
extensive enzymatic metabolism, but shells and coatings are. The extent of metabolism of the
shell and coating becomes critical for toxicity, since they shield the more toxic CdSe or CdTe
cores from the intracellular environment. Rather than metabolism per se, degradation of the
shell and coatings within the biological environment appear to be more important. QD shells
and coatings appear to degrade under photolytic and oxidative conditions, yet we know little
about the degradation products or their biological effects, which may regulate release of toxic
cadmium cores. The behavior of nanoparticles in vivo depend on properties such as the
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nanosize (surface area and size distribution), chemical composition (purity, crystallinity,
electronic property, etc.), surface structure (surface reactivity, surface groups, inorganic or
organic coatings, etc.), solubility, shape, and aggregation [115]. It has been suggested that the
metabolic paths of QD nanoparticles are closely correlated to their aggregation states, and three
metabolic paths were disclosed after intravenous injection: 1) the QDs that maintained their
original nanosize without binding in vivo were rapidly excreted via the kidney; 2) some QDs
binding to proteins were translocated to the liver and were excreted with feces; 3) a small
Figure 5. Photographs of 72 h-old chick embryos treated with CdS/Maltodextrin. Observed alterations were dose de‐
pendent.
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fraction of the QDs aggregated to larger particles and were retained in liver tissue for a long
time [116].
Several studies suggest that the kidneys can remove QDs that are less than 5 nm. It has been
observed that, after i.v. administration of CdSe/ZnS-QDs, only 10% and 40% of the injected
dose was found in the kidney and liver respectively, suggesting that only a fraction of the total
QDs dose passed through this route [117]. Another study quantitatively detected the excretion
of QDs in mice feces and urine after i.v. injection of CDSe QDs. The speed of excretion was
quicker via feces, and the peak (0.214 ng of Cd) occurred 6–12 h postexposure. The excretion
from urine was relatively delayed, and the peak (0.174 ng of Cd) was 24–36 h post-exposure
[118]. The elimination of silica-coated CdSe QDs (~5.5 nm) from the body via feces and urine
occurred in its totality after 5 days. Yet many reports propose that a portion of the administered
QD dose may not be excreted and remains in the tissues. The extent of excretion and the extent
of persistence in tissues take on added importance when one considers the potential delivery
of QD as a cancer-targeting drug. More comprehensive studies of potential excretion will
therefore be critical to QD development as a nanopharmaceutical.
Numerous studies have addressed the cellular level, but these are often difficult to compare
due to varied dosing parameters and lack of physicochemical particle characterization. In
general, it appears that most QDs examined found ready uptake at the cellular level, primarily
via endocytic mechanisms, which depends upon the surface ligands coated over the QD
surface [119, 23]. It has been reported that CdSe QDs and CdTe QDs that enter the cell, are
visible at the cell surface and in the cytoplasm after a short time. QDs are likely to bind to the
cell surface due to their interaction with cell surface glycoproteins and glycolipids [66].
Employing red-and green-emitting cationic QDs, it was found that the CdTe QD distribution
was in part dependent on nanoparticle size. In the murine microglial N9 cell line, red cationic
QDs (5 nm) were distributed throughout the cytoplasm. In contrast, green and also positively
charged QDs (2 nm) were often found in the nucleus of N9 cells upon 1 h of QD exposure [120].
It has been shown that green QDs coated with tri-metoxysilylprolyl urea and acetate groups
bind with high affinity in the cell nucleus of mouse 3T3 fibroblasts [121]. In human mammary
epithelial tumor cells (MDA-MB-231) green-emitting CdSe/ZnS/SiO2 QDs were packaged in
large vesicles found in the perinuclear region [23]. Confocal images have showed that MPA-
coated QDs were distributed inside the cytoplasmic region of cells. In contrast, GA/TOPO-
coated QDs were not found inside cells. These results indicate that cellular uptake of QDs
depends upon the hydrodynamic size of the QDs as well as surface coating material [122].
These results strongly suggest that surface coatings can improve cytocompatibility and,
consequently, decrease toxicity. Previous studies have shown that long-term exposure of
surface coated QDs to their bioenvironment can destabilize the binding strength of the surface
molecules, which in turn can yield unprotected QDs inside or outside the cells [123]. Therefore,
the stability and binding strength of surface molecules over the QD surface define the cyto‐
compatibility of the QDs and hence their cytotoxicity. Thus, according to previous studies: (1)
the surface coating strategy could improve the cytocompatibility of QDs, (2) surface molecules
could determine the intracellular uptake and consequent cytotoxicity of QDs, and (3) intra‐
cellular uptake of QDs could depend on their hydrodynamic size.
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7. Strategies for safe drug delivery using cadmium-containing quantum
dots
Discussion regarding the toxicity of cadmium-containing QDs can be somewhat confusing
because of the diversity QDs being synthesized. Besides and as we have mentioned before, we
have to consider that not all QDs are alike. Each individual type of QD possesses its own unique
physicochemical properties, which in turn determine its potential toxicity or lack thereof [124].
In general, there are discrepancies in the current literature regarding the toxicity of QDs and
these can be attributed to several factors: the lack of toxicology-based studies, the variety of
QD dosage/exposure concentrations reported in the literature, and the widely varying
physicochemical properties of individual QDs.
Up to date, toxicity studies have been conducted on a variety of both human and non-human
cells and cell lines; research has been focused on in vitro assays of cytotoxicity [125-131]. In
vitro studies are very important and can serve as background data to inform the design of in
vivo studies but, on their own, they provide an insufficient basis for a complete risk assessment.
Administration of QDs in animal models has revealed that QDs induce: (1) accumulation of
QDs in specific organs [23, 132, 133], (2) excretion in urine, bilis and feces [134], (3) toxicity in
selective organs [135], (4) embryotoxicity [109, 111], and (5) oxidative damage [136-138].
Importantly, and a potential source of confusion in assessing QD toxicity, the latter depends
on multiple factors derived from both individual QD physicochemical properties and envi‐
ronmental conditions: QD size, charge, concentration, outer coating bioactivity (capping
material, functional groups), and oxidative, photolytic, and mechanical stability have each
been shown to be determining toxicity factors. Therefore, all these aspects should be extended
to examine alternate QD formulations, compositions, and shapes to help facilitate any future
generalizations regarding size thresholds in the regulatory context. There are only a few
studies specifically designed for toxicological assessment (e.g., dose, duration, frequency of
exposure, mechanisms of action). Many of the studies, from which QD toxicity information is
derived, it has been cited in reference to it were performed by nanotechnology researchers
rather than toxicologists or health scientists. It is therefore difficult to extrapolate the results
of such studies in order to reach any conclusions regarding the health and safety of QDs.
Nonetheless, these studies may provide important insights that will be useful in guiding the
eventual design of standardized toxicity tests and protocols.
The wealth of data accumulated from QD toxicity studies is an invaluable asset that should be
exploited to design appropriate methodologies to further assess the toxicity of novel QDs.
Researchers often neglect to carry out a comprehensive characterization of QDs prior to using
them. In our opinion, this step is absolutely necessary, especially before any toxicity screening
is started, precisely because the exact property or properties of QDs responsible for said toxicity
are still poorly understood. This omission is one of the reasons behind the current state of
confusion surrounding this issue. As epigenetic changes may lead to long-term reprogram‐
ming of gene expression long after the initial insult has been removed, results from “nanoe‐
pigenetic” assessments may have important implications on the future use of new
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nanomaterials in bioimaging and therapeutic applications. They should be evaluated early in
the development of new QDs as well as QD-based devices and clinical tools. Future QD toxicity
studies should be standardized and systematized because methodological variability in the
current body of literature makes it difficult to compare and contrast results. We advocate the
following steps for consistent, comparable toxicology data: (a) standardize dose metrics, (b)
characterize QD uptake concentration, (c) identify in vitro models that reflect how the QDs
QDs interact with cells in vivo, and (d) use multiple assays to determine sublethal toxicity and
biocompatibility. Proceeding without careful evaluation of these critical areas will blunt the
progress of nanomedicine and place human health at risk. However, judicious further research
into these areas will undoubtedly contribute to development of nanopharmaceuticals for
cancer treatment and drug delivery that have minimal to low risk and can highly benefit public
health.
8. Conclusion
Cadmium-containing QDs are leading the way toward new preparations that can overcome
the fundamental limitations of simple free drug formulations, providing the means to change
their pharmacological properties and also understand their biological fate in great detail.
However, ADME properties depend on multiple factors derived from both inherent physico‐
chemical properties and environmental conditions. The findings also suggest that, under
certain conditions, QDs may pose risks to human health, as determined by rodent animal
models and in vitro cell cultures. This review outlined the unique features that make QDs an
ideal platform for nanocarrier design and discussed how this model has been applied to study
vehicle behavior for diverse drug delivery applications. However, it is clear that to make such
a goal feasible and relatively risk-free for human beings, more extensive pharmacological and
toxicological research of QDs are needed.
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